Introduction {#Sec1}
============

A growing body of evidence has indicated that omega-3 polyunsaturated fatty acids (omega-3 PUFAs) have been effective in improving depression^[@CR1],[@CR2]^. Supplementation with the two main types of omega-3 PUFAs, eicosapentaenoic acid (EPA)^[@CR3]^, and docosahexaenoic acid (DHA)^[@CR4],[@CR5]^, has also been found to be effective in reducing symptoms of depression. However, EPA and DHA may play different roles in depression because of their involvement in anti-inflammatory activity and their maintenance of membrane integrity and fluidity, respectively^[@CR6]^. The different therapeutic effects of EPA and DHA on depression need to be further studied.

The treatment efficacy of supplementation with omega-3 PUFAs in depression is influenced by the proportion and dosage of EPA or DHA. Previous meta-analyses have proposed that PUFAs that are mainly EPA (EPA \> 50%^[@CR7]^, 60%^[@CR8]^, and 80%^[@CR9]^ of the dose) have significantly greater efficacy than those that are mainly DHA (DHA \> 50%, 60%, and 80% of the dose, respectively), regardless of PUFAs monotherapy or adjuvant use. Some studies have also demonstrated that different dosages of EPA and DHA may result in different levels of efficacy. Recent double-blinded randomized controlled trials (RCTs) indicated that EPA, mostly at dosages of 1 or 2 g/d, was better (than placebo and DHA) as a monotherapy or adjuvant in the treatment of mild to moderate depression and that the ratio of an 'active' synergetic effect between EPA and DHA would probably be either 2:1 or 3:1^[@CR10]--[@CR12]^. Regarding DHA supplementation, Mischoulon et al. also reported that compared to 4 g/d, greater efficacy was found at 1 g/d and 2 g/d in a single-arm randomized trial on depression^[@CR5]^.

Given the discrepancy in these methodological aspects, the results would be interpreted differently in each of the previously mentioned studies. However, whether and how EPA and DHA initiate their effects on depression differentially or synergistically with regard to dosage and proportion are still unclear. Therefore, we conducted this meta-analysis to provide an update on the therapeutic effect of omega-3 PUFAs and on the associations between EPA or DHA supplementation and depression, including the effects of the dosage and proportion of EPA or DHA supplementation on depression.

Materials and methods {#Sec2}
=====================

Search strategy {#Sec3}
---------------

We conducted a systematic bibliographic search for studies that examined the role of omega-3 PUFAs in depression using "major depressive disorder", "depression", "fatty acid, omega-3", and "randomized controlled trial" as key words. We applied our search in the following databases, from inception to 20 December 2017: PubMed and the Ovid version of EMBASE (Supplementary [1](#MOESM1){ref-type="media"}). We also searched the references of selected studies and earlier meta-analyses to identify additional potential studies for inclusion in our analysis.

Study selection {#Sec4}
---------------

Two independent, trained reviewers screened the identified articles for their relevance by title/abstract and full text. Discrepancies between reviewers were resolved by discussion in all cases and if necessary, by arbitration by a third reviewer. Relevant articles were obtained and included in this review if they had the following characteristics: (1) a double-blind randomized placebo-controlled trial, (2) inclusion of adults with a diagnosis of clinical depression (DSM-III-R/DSM-IV) or depressive symptoms according to validated psychometric instruments (with or without comorbid medical conditions), and (3) clear dosage and duration of EPA and DHA intake. We excluded studies with the following characteristics: (1) depression secondary to other neuropsychiatric disorders and (2) perinatal major depressive disorder.

Assessment of risk of bias {#Sec5}
--------------------------

Two reviewers independently assessed the risk of bias for each study using the criteria outlined in the *Cochrane Handbook for Systematic Reviews of Interventions*^[@CR13]^. We resolved disagreements by discussion, and we assessed the risk of bias according to the following categories: (1) selection bias, (2) performance bias, (3) detection bias, (4) attrition bias, (5) reporting bias, and (6) other bias.

We judged each potential source of bias as high, low, or unclear risk and have provided a supporting quotation from the study report together with a justification for our judgment in each 'Risk of bias' table (Supplementary [2](#MOESM2){ref-type="media"}).

Data extraction {#Sec6}
---------------

Two reviewers independently assessed and extracted relevant data, including participants' demographic characteristics, type of clinical diagnosis, psychometric instruments, treatment duration, type and dosage of compound administered, sample size, and psychometric score means and standard deviations (SDs). If the included studies did not report concrete data, we contacted the authors to obtain this information. Our primary analysis used the following hierarchy of psychometric instruments: (1) the Hamilton Rating Scale for Depression (HRSD), (2) the Montgomery-Asberg Depression Rating Scale (MADRS), (3) the Beck Depression Inventory (BDI), and (4) the primary outcome of the selected study.

We divided the omega-3 PUFAs into 4 categories: DHA-pure, DHA-major, EPA-pure, and EPA-major. The DHA- and EPA-pure trials were those in which the omega-3 PUFA supplementation contained only DHA or EPA, respectively. The DHA- and EPA-major categories were those providing higher quantities of DHA (≥60%) or EPA (≥60%), respectively, compared with other omega-3 PUFAs. We further divided the dosages of EPA into ≤1.0 g/d and \>1.0 g/d.

Statistical analysis {#Sec7}
--------------------

We used standardized mean differences as the summary statistic for continuous data by attaining the mean (SD) and sample size (n) of the omega-3 PUFAs and placebo groups. When SDs were not available, we estimated them based on the other statistical parameters reported in the study or requested by authors. All data were analyzed at a single point at the end of the trial. We calculated the Q-statistic to estimate the heterogeneity, and *P* ≤ 0.01 was considered statistically significant for the Q-statistic test. The *I*^2^ statistic was used to quantify heterogeneity, and an *I*^2^-value of 0% indicated no observed heterogeneity, with larger values showing increased heterogeneity. Given the expected heterogeneity, we a priori used a random-effects model. Fixed-effects models would be applied when *I*^*2*^ was \<75%. A sensitivity analysis was performed by excluding low-quality studies, trials recruiting participants with particular conditions, or trials with characteristics that were different from those in the other trials. Publication bias was assessed with a funnel plot and Egger's test. Egger's linear regression test was used to evaluate asymmetry, and *P* \< 0.05 was set as the level of significance. All statistical analyses were performed using RevMan 5.3 (RevMan; The Cochrane Collaboration, Oxford, UK) and R 3.4.3 (R; GitHub, San Francisco, US).

Results {#Sec8}
=======

Selection of studies {#Sec9}
--------------------

An outline of the search strategy is presented in Supplementary [1](#MOESM1){ref-type="media"}. From the searches for recently published RCTs in the databases, 179 records were identified. Of these, 173 records were reviewed, and 16 trials met the eligibility criteria. From the searches for systematic reviews or meta-analyses, 25 potential records were identified, and 12 RCTs met the eligibility criteria. Two studies describing results that came from the same trial were removed^[@CR14],[@CR15]^. Ultimately, 26 trials were included in our meta-analysis (Fig. [1](#Fig1){ref-type="fig"}), and details of these trials are displayed in Table [1](#Tab1){ref-type="table"}. Among these trials, 12 showed a significant effect of omega-3 PUFAs on the selected rating scales. The risk of bias for all included trials was assessed by the Cochrane methods, and the results can be seen in supplementary [2](#MOESM2){ref-type="media"}.Fig. 1**Flow chart of literature search and study selection**. This figure described the route of studies inclusion. Among 204 researches from database and other studies, there are 26 trials were satisfied for the criteria of our study. MDD major depressive disorder, RCT randomized control trialTable 1Systematic review of RCTs of omega-3 PUFAs for depressionAuthorYearAgeComorbidityAntidepressantsClinical diagnosisRating scalesDurationOmega-3 PUFAsEPADHA1. Peet & Horrobin (1 g/d)^[@CR16]^200218--70MixedWithWithoutHDRS-17/ MADRS/BDI12 weeks1000 mg/d/Peet & Horrobin (2 g/d)--------------2000 mg/d/Peet & Horrobin (4 g/d)--------------4000 mg/d/2. Nemets et al.^[@CR17]^200218--75MixedMixedDSM-IVHDRS-244 weeks2000 mg/d/3. Su et al.^[@CR18]^200318--60WithoutMixedDSM-IVHRSD-218 weeks880 mg/d440 mg/d4. Marangell et al.^[@CR4]^200318--65WithoutWithoutDSM-IVHDRS-28/ MADRS6 weeks/2000 mg/d5. Hallahan et al.^[@CR19]^200716--64WithoutWithDSM-IIIHRSD-17/ BDI12 weeks1200 mg/d900 mg/d6. Grenyer et al.^[@CR20]^200718--75WithMixedDSM-IVHDRS-1716 weeks2200 mg/d600 mg/d7. Jazayeri et al.^[@CR21]^200820--59WithoutWithoutDSM-IVHDRS-248 weeks1000 mg/d/8. Rogers et al.^[@CR22]^200818--70MixedWithoutWithoutBDI/ DASS12 weeks630 mg/d830 mg/d9. Lucas et al.^[@CR23]^200944--55WithoutWithoutDSM-IVHAMD-218 weeks1150 mg/d150 mg/d10. Carney et al.^[@CR24]^2009adultWithWithDSM-IVHAMD-17/ BDI-II10 weeks930 mg/d750 mg/d11. Mischoulon et al.^[@CR11]^200918--80WithoutMixedDSM-IVHAMD-178 weeks970 mg/d/12. Bot et al.^[@CR25]^201018--75WithWithDSM-IVMADRS12 weeks1000 mg/d/13. Coryell (1 g/d)201018--55MixedWithDSM-IVMADRS6 weeks740 mg/d400 mg/d Coryell (2 g/d)--------------1480 mg/d800 mg/d14. Rondannelli et al.^[@CR26]^201165--95MixedWithoutDSM-IVGDS8 weeks1670 mg/d830 mg/d15. Tajalizadekhoob et al.^[@CR27]^2011≥65WithMixedWithoutGDS-156 months180 mg/d120 mg/d16. Antypa et al.^[@CR28]^201218--65WithoutMixedWithoutBDI4 weeks1740 mg/d250 mg/d17. Gertsik et al.^[@CR29]^201218--65MixedWithDSM-IVHAMD-218 weeks900 mg/d200 mg/d18. Lespérance et al.^[@CR30]^2012≥18MixedWithWithoutMADRS8 weeks1050 mg/d150 mg/d19. Mozaffari-Khosravi et al. (DHA)^[@CR3]^201318--75WithoutWithDSM-IVHDRS-1712 weeks/1000 mg/dMozaffari-Khosravi (EPA)--------------1000 mg/d/20. Gharekhani^[@CR31]^2014AdultsWithWithoutWithoutBDI-2112 weeks1080 mg/d720 mg/d21. Mischoulon et al. (DHA)^[@CR32]^201518--80WithoutWithoutDSM-IVHDRS-178 weeks180 mg/d900 mg/dMischoulon (EPA)--------------1060 mg/d274 mg/d22. Park et al.^[@CR33]^201518--65WithoutWithDSM-IVHAMD-1712 weeks1140 mg/d600 mg/d23. Ravi et al.^[@CR34]^201618--65WithWithoutWithoutBDI8 weeks720 mg/d480 mg/d24. Mazereeuw et al.^[@CR35]^201645--80WithMixedDSM-IVHAMD-17/ BDI-II12 weeks1200 mg/d600 mg/d25. Shinto et al.^[@CR36]^201618--85WithWithDSM-IVMADRS/ BDI3 months1950 mg/d1350 mg/d26. Rapaport et al. (DHA)^[@CR37]^201618--80WithoutMixedDSM-IVHAMD-178 weeks180 mg/d900 mg/d Rapaport (EPA)2016------------1160 mg/d260 mg/dAll 26 trials included in this meta-analysis were double-blind, randomized controlled trials. They were summarized as participants' age, including with or without clinical diagnosis, kinds of rating scales, received therapy dosage and duration*DSM-IV* Diagnostic and Statistical Manual of Mental Disorders (fourth edition), *DSM-III* Diagnostic and Statistical Manual of Mental Disorders (third edition), *HDRS/HAMD-17/21/24* 17/21/24-item Hamilton Depression Rating Scale, *MADRS* Montgomery Asberg Depression Rating Scale, *BDI* Beck Depression Inventory, *GDS* Geriatric Depression Scale, *omega-3 PUFAs* omega-3 polyunsaturated fatty acids, *EPA* eicosapentaenoic acid, *DHA* docosahexaenoic acid

Meta-analysis {#Sec10}
-------------

### Omega-3 PUFAs efficacy {#Sec11}

A total of 1089 and 1071 subjects were included in the omega-3 PUFAs supplementation group and placebo group, respectively. Analysis was based on the HRSD score in 16 studies^[@CR3],[@CR4],[@CR11],[@CR16]--[@CR21],[@CR23],[@CR24],[@CR29],[@CR32],[@CR33],[@CR35],[@CR37]^, MADRS score in 4 studies (including one unpublished study, Coryell)^[@CR25],[@CR30],[@CR36]^, BDI score in 4 studies^[@CR22],[@CR28],[@CR31],[@CR34]^ and other scales (The Geriatric Depression Scale, GDS) in 2 studies^[@CR26],[@CR27]^. Overall, omega-3 PUFAs had significant effects on the improvement of depression (Fig. [2](#Fig2){ref-type="fig"}); however, the effect sizes were small to modest, and substantial evidence of heterogeneity between studies was detected (*I*² = 75%).Fig. 2**Forest plot: omega-3 PUFAs vs control**. There was significant effect of omega-3 PUFAs therapy for depression compared to placebo using random effect model. There was also significant evidence of heterogeneity between trials. Size of green plot proportional to weight in meta-analysis. Black lines, show confidence intervals. SD standard deviation, Std. Mean difference standardized mean difference, IV. Random Random (inverse variance heterogeneity), CI confidence interval

### DHA and EPA efficacy {#Sec12}

Overall, 2 study groups were classified as DHA-pure^[@CR3],[@CR4]^; 3 study groups, DHA-major^[@CR22],[@CR32],[@CR37]^; 8 study groups, EPA-pure^[@CR3],[@CR11],[@CR16],[@CR17],[@CR21],[@CR25]^; and 16 study groups, EPA-major (including one unpublished study, Coryell)^[@CR18],[@CR20],[@CR23],[@CR26]--[@CR35],[@CR37]^. For the subgroup analysis of the concentration of omega-3 PUFAs treatments, DHA-pure and DHA-major treatments failed to show significant efficacy in improving depression (SMD = −0.39, *P* = 0.34, and SMD = 0.11, *P* = 0.95, for the fixed-effects and random-effects models, respectively), while EPA-pure and EPA-major treatments were beneficial in improving depression (SMD = −0.48, *P* \< 0.001, and SMD = −0.33, *P* = 0.05, for the fixed-effects and random-effects models, respectively).

### EPA dosage efficacy {#Sec13}

The dosage of EPA supplementation ranged from 180 mg/d to 4000 mg/d. We separated the EPA-pure and EPA-major groups into ≤1 g/d and \>1 g/d, depending on the EPA dosage. The results indicated that with an EPA dosage ≤1 g/d, the EPA-pure and EPA-major groups demonstrated significant beneficial effects on the improvement of depression (SMD = −0.50, *P* = 0.003, and SMD = −1.03, *P* = 0.03, for the fixed-effects and random-effects models, respectively). We then set a dosage boundary of 1.5 g/d and 2 g/d, but no significant results were detected. Furthermore, we also set a boundary of 50% EPA in omega-3 PUFA supplementation, but we did not observe any of the significant findings for the analyses of different dosage subgroups mentioned above.

### Publication bias and sensitivity analysis {#Sec14}

Our funnel plot and statistical test showed no evidence of publication bias (Fig. [3](#Fig3){ref-type="fig"}, Egger's test *P* = 0.17). Running the sensitivity analysis by excluding some high-risk^[@CR21],[@CR29],[@CR31],[@CR33]^ and unpublished studies (Coryell) had no remarkable effect on the results \[SMD = −0.25, 95%CI (−0.46, −0.04), *P* \< 0.001, random-effects model\]. Excluding studies with specific comorbid chronic physical diseases also did not substantially change the results \[SMD = −0.22, 95%CI (−0.38, −0.06), *P* \< 0.001, random-effects model\].Fig. 3**Funnel plot of effect sizes for clinical trials included in the meta-analysis**. This funnel plot depicts the standardized mean difference of trials versus their standard error. Published trials are depicted as dark circles. The dotted line bracket the 95% CI for the expect results of trials given this estimated underlying effect size

Discussion {#Sec15}
==========

Herein, we found that omega-3 PUFAs demonstrated a therapeutic effect of −0.28 (95%CI: −0.47, −0.09) on the improvement of depression. Among them, with a dosage of EPA ≤ 1 g/d, the EPA-pure and EPA-major groups demonstrated better effect sizes on the improvement of depression. This effect was in line with those of previous studies^[@CR2],[@CR9],[@CR12]^ and may be mediated by the known mechanism of omega-3 PUFAs at the cellular level^[@CR38]^. In general, omega-3 PUFAs are the essential fatty acids used to produce EPA; from EPA, they then synthesize DHA. However, whether DHA, EPA or both actually contribute to improvements in depression is a topic of considerable debate in current studies. Hence, the subgroup analysis in our meta-analysis demonstrated that only both EPA-pure and EPA-major treatments had favorable effectiveness in depression improvement. This finding was consistent with that of a review by Song et al., which found that the ratio of EPA to DHA that would be most effective for depression was 2:1 or 3:1^[@CR12]^. Similarly, two meta-analyses considered that the effective proportion of EPA in depression were EPA ≥60%^[@CR8]^ and ≥80%^[@CR9]^ respectively. However, the authors examined RCTs including participants with bipolar disorder and Parkinson's disease and women who were pregnant, which would interfere with the efficacy of omega-3 PUFAs for depression^[@CR38]^. In contrast, another recent meta-analysis set the lower boundary of the proportion of EPA in omega-3 PUFA supplementation at 50% and showed significant effectiveness^[@CR7]^. However, that study also included participants with a secondary diagnosis of depression. These results might be related to differences in the metabolism of EPA and DHA. To the best of our knowledge, although EPA is more efficacious with regard to its antidepressant effect, the relationship between EPA and DHA in depression therapy remains unclear. We cannot determine whether the efficacy occurs because of EPA alone or because of an interaction with DHA supplementation. Some possible mechanisms are demonstrated below.

In contrast to DHA, EPA is not highly concentrated in the human brain at steady state. EPA can rapidly enter the brain as a free fatty acid and is not re-acylated into phospholipid membrane stores because it is quickly metabolized and beta-oxidized to act as an effector^[@CR39]^. Based on this process, in the last decade, the contribution of inflammation to depression has been extensively documented^[@CR40],[@CR41]^, and both DHA and EPA or EPA alone may reduce the occurrence of inflammation (eicosanoids). In the first mechanism, DHA and EPA can lead to decrease in production of proinflammatory cytokines, such as tumor necrosis factor (TNF)-α^[@CR42]^, interleukin (IL)-1β, IL-2, and IL-6, which are determined by eicosanoid discharge and related to depression. Furthermore, both DHA and EPA can reduce inflammation through their precursor arachidonic acid. DHA and EPA combine with arachidonic acid for amalgamation into membrane-based phospholipids, leading to a decline in both cellular and plasma concentrations of arachidonic acid.

The other possibility is that EPA, but not DHA, can decrease the production of arachidonic acid by inhibiting delta-5-desaturase activity. In the cyclooxygenase enzyme system, EPA may compete with arachidonic acid for phospholipase A~2~ (PLA~2~) and help block the process of proinflammatory eicosanoid synthesis from arachidonic acid (e.g., prostaglandins, thromboxanes, and leukotrienes), prostaglandin E2 and thromboxane B2^[@CR38]^. In addition, one study determined that individuals with elevated interferon (IFN)-α levels that resulted from chronic hepatitis C always meet operational diagnostic criteria for depression^[@CR43]^, and a recent RCT pointed out that EPA but not DHA ameliorated IFN-α-induced depression^[@CR44]^. Overall, although we cannot ignore the contribution of DHA to the depression-related metabolic pathway, the unique antidepressant effects of EPA make it more appealing.

In addition to the anti-inflammatory effect, other mechanisms can explain the advantages of EPA supplementation. First, EPA supplementation has been associated with *N*-acetyl-aspartate increases in the brain, a marker for neuronal homeostasis, suggesting its role as a neuroprotective agent^[@CR45]^. EPA supplementation also increased the ratio of cerebral phosphomonoesters to phosphodiesters, an indicator of phospholipid turnover, and reversed brain atrophy in a subject with major depressive disorder^[@CR46]^. Second, EPA is the natural ligand for the peroxisome proliferator-activated receptor gamma (PPARγ) nuclear transcription receptor that downregulates the expression of nuclear factor-kappa B (Nf-kB) and inhibits the neuronal parainflammatory cascades implicated in the pathophysiology of depression^[@CR47]^. Low concentrations of EPA could bind with very high affinity to all PPARs, whereas DHA binding is too low to be measured, and DHA may provide tonic inhibition of PPARs at high concentrations^[@CR48]--[@CR51]^. Third, in the rodent olfactory bulbectomy depression model, EPA treatment normalized depressive behaviors by attenuating prostaglandin E~2~-mediated activation of IL-6, decreasing mRNA expression for corticotrophin-releasing hormone (CRH) and inhibiting hyperactivation of the hypothalamic-pituitary-adrenal (HPA) axis^[@CR52]^. EPA may also exert a greater neurotrophic effect than DHA, as EPA supplementation has been shown to increase brain-derived neurotrophic factor (BDNF) levels after traumatic brain injury^[@CR53],[@CR54]^. Finally, EPA may be partly related to the brain's ability to increase dopaminergic and serotonergic neurotransmission^[@CR55]^.

Based on the significant proportion of EPA supplementation in our results, we also conducted a subgroup analysis to examine the antidepressant effect of its dosage. We found no apparent benefit of a higher dosage (\>1 g/d) of either EPA-pure or EPA-major treatment for depression. Depending on the significant difference between EPA dosage groups, our included studies may confirm that the efficacy of EPA is dose dependent. Two assumptions can probably provide explanations. First, in omega-3 PUFAs supplementation for patients with Alzheimer's disease, EPA could significantly increase to approximately 50 ng/mL in cerebrospinal fluid (CSF) with an intake of 150 mg/d, while DHA increased to only 30 ng/mL based on a dose of 430 mg/d^[@CR56]^. This finding might suggest a difference in the handling of these two PUFAs during the passage from blood across the blood-brain barrier (BBB) to the central nervous system (CNS) and also serves as a reminder that low doses of dietary EPA intake may be sufficient to have therapeutic effects on depression. Second, a study demonstrated that EPA at high dosages may hamper the activity of CYP2D6 and CYP2A4, which are considered major enzymes in the metabolism of antidepressant drugs (selective serotonin reuptake inhibitors, SSRIs). With the lower boundary of significant EPA supplementation at 720 g/d, we concluded that EPA at proportions of 60% and above in omega-3 PUFAs and a range of 720 mg/d to 1000 mg/d may be more effective in improving depression.

Depended on the efficacy of EPA concentration and dosage, we still cannot neglect the applicable population for this treatment. Considering the patients in augmentation studies may be different from monotherapy through treatment -- resistant and severity of depression, we conducted subgroup analysis and only detected the significant effectiveness of augmentation group with EPA-pure (SMD = −0.44, 95% CI −0.81 to −0.06, *P* = 0.02, fixed-effects model, 3 studies and 135 subjects). However, the number of studies and subjects were small, and confidence interval was wide. It may be insufficient to support the efficacy of EPA augmentation. However, there was one meta-analysis demonstrated that EPA was effective in both monotherapy and augmentation^[@CR9]^, two studies demonstrated a greater antidepressant efficacy of EPA augmentation compared with monotherapy studies^[@CR9],[@CR21]^. Since EPA is highly correlated with inflammation, a proof-of-concept study revealed that EPA supplementation might benefit only major depressive disorder (MDD) subjects with inflammation as part of their syndrome and that it may even be potentially harmful for individuals whose MDD was due to a different physiological disturbance^[@CR37]^. It may remind us that, in the case of monotherapy and augmentation, the effective supplementation of EPA depends to a large extent on the pathogenesis of the depression patient.

The main limitation of this study was the inability to control for the many potential sources of heterogeneity, including baseline levels of depression, sex, BMI, and baseline plasma omega-3 PUFAs levels. Secondly, we were unable to obtain concrete data describing the subgroup analysis of EPA monotherapy and augmentation sufficiently, as well as the inflammatory biomarkers for all included trials, but the clinical usage of EPA supplementation warrants our attention. In addition, we cannot neglect the efficacy of DHA. In our results, only two RCTs included DHA-pure and DHA-major groups, which was not sufficient to explore the effective proportion and dosage of DHA in omega-3 PUFAs supplementation. Future studies are necessary to address whether DHA or EPA or a combination of the two acting synergistically or antagonistically depends on the specific subgroup of MDD. Finally, the dose effects and the relationship between dietary intake and brain levels of in vivo human omega-3 PUFAs still need to be further studied. The strength of our meta-analysis is that we set strict inclusion criteria for existing RCTs, with a specific focus on excluding certain mental illnesses that would confound the efficacy of omega-3 PUFAs for depression.

Omega-3 PUFAs with formulations containing ≥60% EPA demonstrated antidepressant effects when EPA ≤ 1 g/d. Although many trials support these meta-analysis results, we should nonetheless recognize the heterogeneity among these trials and pay more attention to the proportion and dosage of both DHA and EPA supplementation, including whether they have opposite effects in the case of a 1:1 ratio and how much EPA is effective in improving depression. We note that the long-term efficacy and health effects of omega-3 PUFA supplementation in depression have yet to be elucidated.
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